EBV-MS
Targeting the Epstein-Barr virus to treat and prevent MS (EBV-MS) is a ground-breaking Horizon Europe-funded research project with leading universities and hospitals in Europe and the USA. We are aiming to unveil the role of the Epstein-Barr virus (EBV) in the onset and progression of the Multiple Sclerosis (MS) disease.
About the research project
The aim of the project, led by the University of Bergen, is to understand why only a few EBV infected people develop MS, and define the underlying mechanism of this process. The project will also investigate whether targeting the EBV infection with antiviral treatments can improve the disease course or stop disease progression.
Project managers
- Kjell-Morten Myhr, Project Manager, e-mail: kjell-morten.myhr@uib.no
- Øivind F. Grytten Torkildsen, Deputy Project Coordinator, e-mail: Oivind.Torkildsen@uib.no
Featured
People
Project manager
Kjell-Morten Myhr Project manager, e-mail kjell-morten.myhr@uib.no, tel. +47 55976031 / +47 41447868
Øivind F. Grytten Torkildsen Deputy Project Coordinator, e-mail: Oivind.Torkildsen@uib.no
Other EBV-MS Project office contacts
Yamila Torres Cleuren Scientific Project Manager, e-mail: Yamila.cleuren@uib.no, tel: +47 55585431
Janniche Torsvik Scientific Project Manager, e-mail: janniche.torsvik@uib.no
Mona Machrouh (maternity leave) Scientific Project Manager, e-mail: mona.machrouh@uib.no, tel: +47 55589111
Hege Høiland Project Financial Manager, e-mail: hege.hoiland@uib.no, tel: +47 55584974
Funding
This project has received funding from the European Union’s Horizon Europe Research and Innovation Actions under grant no. 101136991 (EBV-MS). Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.